The burgeoning popularity of tirzepatide , initially for diabetes , is creating significant buzz within the United Kingdom , prompting a notable shift in hormone trends. Access these treatments remains a complex landscape, with National Health Service provision currently limited and private clinics offering prescriptions at a higher cost . Question